Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer
Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence. The FDA has approved Pfizer’s Braftovi and Mektovi for treating metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations, the agency said Wednesday. Pfizer…#pfizer #fda #nsclc #novartis #braf #xalkori #vizimproforegfr #pharos #braftovi #mektovi
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Health | Lung Cancer | Non-Small Cell Lung Cancer | Pfizer | Pharmaceuticals